Health Care & Life Sciences » Biotechnology | Basilea Pharmaceutica AG

Basilea Pharmaceutica AG | Balance Sheet

Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
273,900.00
226,100.00
365,000.00
239,000.00
260,724.00
223,908
Total Accounts Receivable
7,300.00
8,200.00
5,000.00
7,000.00
15,026.00
34,719
Inventories
-
4,900.00
9,600.00
14,900.00
15,320.00
14,411
Other Current Assets
5,000.00
5,400.00
5,400.00
7,100.00
1,906.00
1,700
Total Current Assets
286,200.00
244,600.00
385,000.00
268,000.00
292,976.00
274,738
Net Property, Plant & Equipment
13,000.00
12,200.00
10,700.00
8,900.00
7,768.00
6,424
Total Investments and Advances
-
-
-
50,000.00
50,000.00
-
Intangible Assets
400.00
200.00
300.00
200.00
326.00
372
Other Assets
200.00
400.00
3,000.00
900.00
95.00
217
Total Assets
299,800.00
257,400.00
399,000.00
328,000.00
351,165.00
281,751
Accounts Payable
1,700.00
2,100.00
1,000.00
2,000.00
4,353.00
Income Tax Payable
-
-
-
-
5,600.00
Other Current Liabilities
58,600.00
59,600.00
68,000.00
71,000.00
69,538.00
Total Current Liabilities
60,300.00
61,700.00
69,000.00
73,000.00
79,491.00
Long-Term Debt
-
-
195,000.00
195,000.00
196,224.00
Provision for Risks & Charges
-
9,200.00
13,000.00
20,000.00
16,487.00
Other Liabilities
168,600.00
128,600.00
107,000.00
75,000.00
100,403.00
Total Liabilities
228,900.00
199,500.00
384,000.00
363,000.00
392,605.00
Common Equity (Total)
70,900.00
57,900.00
15,000.00
35,000.00
41,440.00
Total Shareholders' Equity
70,900.00
57,900.00
15,000.00
35,000.00
41,440.00
Total Equity
70,900.00
57,900.00
15,000.00
35,000.00
41,440.00
Liabilities & Shareholders' Equity
299,800.00
257,400.00
399,000.00
328,000.00
351,165.00

About Basilea Pharmaceutica

View Profile
Address
Grenzacherstrasse 487
Basel Basel-Stadt (Basle Town) 4058
Switzerland
Employees -
Website http://www.basilea.com
Updated 07/08/2019
Basilea Pharmaceutica AG is a biopharmaceutical company, with focus on bacterial infections, fungal infections and cancer. The company engages in the discovery, development, and commercialization of pharmaceutical products. Its products include Cresemba Isavuconazole, Zevtera/Mabelio Ceftobiprole, Toctino, and Microbiology Test.